Objetivo
The scientific goals of the proposed prom act are:
1) To develop a array-array system to profile expression levels of drug metabolising enzymes after exposure of cell cultures or whole animals to xenobiotics (drugs or environmental compounds) and
2) to develop an oligonucleotide-array system to detect variant alleles of genes that determine an individuals response to medicinal compounds (drugs) or determine an individuals risk on exposure to environmental toxins. Expression profiling of drug metabolising enzymes in animals and later in humans is a key component in the pre-clinical stages of new drug development in the pharmaceutical industry. Detection of variant alleles (genotyping), the second objective of the proposed collaboration, will address an emerging and far-reaching need in the pharmaceutical industry and in healthcare in general. The ultimate goal of this second objective is to develop a cost-effective method of pharmacogenetic profiling for use as a tool in clinical trial studies and in the longer term as a means of selecting the lost aoorioriate drug therapy for individual patients.
Ámbito científico
Convocatoria de propuestas
Data not availableRégimen de financiación
EAW - Exploratory awardsCoordinador
DUBLIN
Irlanda